Trumab 440mg Injection

Trumab 440mg Injection is a monoclonal antibody called Trastuzumab. It is mainly used to treat HER2-positive cancers including breast and gastric cancer.

Uses of Trumab 440mg Injection:

• Gastric Cancer
• Breast Cancer

How does a Trumab 440mg Injection work?

It targets the HER2 receptor, a protein that is over-expressed on the surfaces of some cancer cells. Trastuzumab binds to HER2 and blocks signalling pathways that drive cell growth and survival, and marks the cells for immune destruction, thus reducing tumour growth.

How to Use & Dosage

The protocol consists of 8 mg/kg followed by 6 mg/kg every three weeks as a maintenance dose. Given as a drip into a vein. The first drips are given slowly to see if there are any side effects.

The medication is given through a vein (intravenously). It is administered by a medical professional specially trained in a hospital or clinic setting.

Ask your paediatrician about using this medicine in children. This drug is not approved for use in children.

Possible Side Effects:

• Nausea
• Vomiting
• Loss of appetite
• Diarrhea
• Fatigue
• Dizziness
• Sweating
• Stomatitis (mouth sores)
• Hand-foot syndrome
• Cardiotoxicity
• Liver enzyme elevation

Safety Advise:

🩸 Liver

The drug can cause toxicity especially in patients with pre-existing conditions and periodic tests for liver function are recommended. Speak with your healthcare provider.

🩺 Kidney

The drug has potential toxicity especially in those patients with pre-existing conditions, so periodic tests for kidney function are advisable. Please see your physician.

🤰 Pregnancy

The use of Trumab in pregnancy is contraindicated because of the risk of fetal harm. Be sure to talk to your health care provider.

🤱 Breast feeding

Breastfeeding should be avoided because the drug can be excreted in breast milk. Talk to your doctor.

Storage Instructions:

Store Trumab Injection in the refrigerator (2-8°C), protected from light. Do not freeze.

References

1. Herceptin (trastuzumab) for Injection, for Intravenous Use: Full Prescribing Information. South San Francisco, CA: Genentech, Inc.
2. Brunton LL, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill.
3. Sweetman SC, ed. Martindale: The Complete Drug Reference. 39th ed. London: Pharmaceutical Press.
4. Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press.
5. Copeland-Halperin RS, Liu JE, Yu AF. Cardiotoxicity of HER2-Targeted Therapies. Current Opinion in Cardiology. 2019;34(4):451-458.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.

Manufacturer details

Name: Glenmark Pharmaceuticals Ltd

Address: Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.

Country of origin: India